Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Denali Therapeutics Inc. (DNLI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 698.18 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 222.07K shares, a 26.92% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 476.12K shares, a 261.43% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 261.85K shares, a 160.00% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 166.29K shares, a 27.06% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 734.84K shares, a 58.34% decline from fiscal 2024.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.76M shares, a 135.47% increase from fiscal 2023.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 749.16K shares, a 36.81% increase from fiscal 2022.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 547.61K shares, a 88.74% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 222.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 698.18K shares 10-Q · filed 2026-08-06 | 960.04K shares derived: sum of 3 quarters · filed 2026-08-06 | 1.13M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 476.12K shares 10-Q · filed 2026-05-07 | 737.97K shares derived: sum of 2 quarters · filed 2026-05-07 | 904.27K shares derived: sum of 3 quarters · filed 2026-05-07 | 1.08M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 261.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 428.15K shares derived: sum of 2 quarters · filed 2026-02-26 | 603.11K shares derived: sum of 3 quarters · filed 2026-02-26 | 734.84K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 166.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 341.25K shares derived: sum of 2 quarters · filed 2025-11-06 | 472.99K shares 10-Q · filed 2025-11-06 | 573.70K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 174.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 306.69K shares 10-Q · filed 2025-08-11 | 407.41K shares derived: sum of 3 quarters · filed 2025-08-11 | 635.40K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 131.73K shares 10-Q · filed 2025-05-06 | 232.44K shares derived: sum of 2 quarters · filed 2025-05-06 | 460.44K shares derived: sum of 3 quarters · filed 2025-05-06 | 1.09M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 100.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 328.71K shares derived: sum of 2 quarters · filed 2025-02-27 | 959.46K shares derived: sum of 3 quarters · filed 2025-02-27 | 1.76M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 228.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 858.75K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.66M shares 10-Q · filed 2024-11-06 | 1.81M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 630.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 1.44M shares 10-Q · filed 2024-08-01 | 1.59M shares derived: sum of 3 quarters · filed 2024-08-01 | 1.77M shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 804.56K shares 10-Q · filed 2024-05-07 | 955.74K shares derived: sum of 2 quarters · filed 2024-05-07 | 1.13M shares derived: sum of 3 quarters · filed 2024-05-07 | 1.36M shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 151.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 330.23K shares derived: sum of 2 quarters · filed 2024-02-28 | 554.86K shares derived: sum of 3 quarters · filed 2024-02-28 | 749.16K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 179.06K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 403.68K shares derived: sum of 2 quarters · filed 2023-11-07 | 597.98K shares 10-Q · filed 2023-11-07 | 650.56K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 224.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 418.93K shares 10-Q · filed 2023-08-08 | 471.50K shares derived: sum of 3 quarters · filed 2023-08-08 | 618.25K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 194.30K shares 10-Q · filed 2023-05-08 | 246.88K shares derived: sum of 2 quarters · filed 2023-05-08 | 393.62K shares derived: sum of 3 quarters · filed 2023-05-08 | 674.82K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 52.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 199.32K shares derived: sum of 2 quarters · filed 2023-02-27 | 480.52K shares derived: sum of 3 quarters · filed 2023-02-27 | 547.61K shares 10-K · filed 2023-02-27 |
| 2022-09-30 | 146.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 427.94K shares derived: sum of 2 quarters · filed 2022-11-03 | 495.03K shares 10-Q · filed 2022-11-03 | 526.10K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 281.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 348.28K shares 10-Q · filed 2022-08-08 | 379.36K shares derived: sum of 3 quarters · filed 2022-08-08 | 507.31K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 67.09K shares 10-Q · filed 2022-05-05 | 98.16K shares derived: sum of 2 quarters · filed 2022-05-05 | 226.12K shares derived: sum of 3 quarters · filed 2022-05-05 | 323.17K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 31.07K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 159.03K shares derived: sum of 2 quarters · filed 2022-02-28 | 256.08K shares derived: sum of 3 quarters · filed 2022-02-28 | 290.13K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 127.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 225.00K shares derived: sum of 2 quarters · filed 2021-11-04 | 259.06K shares 10-Q · filed 2021-11-04 | 353.38K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 97.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 131.10K shares 10-Q · filed 2021-08-04 | 225.42K shares derived: sum of 3 quarters · filed 2021-08-04 | 610.69K shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 34.06K shares 10-Q · filed 2021-05-05 | 128.38K shares derived: sum of 2 quarters · filed 2021-05-05 | 513.64K shares derived: sum of 3 quarters · filed 2021-05-05 | 615.66K shares derived: sum of 4 quarters · filed 2021-05-05 |
| 2020-12-31 | 94.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 479.59K shares derived: sum of 2 quarters · filed 2021-02-26 | 581.61K shares derived: sum of 3 quarters · filed 2021-02-26 | 711.68K shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 385.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 487.29K shares derived: sum of 2 quarters · filed 2020-11-05 | 617.36K shares 10-Q · filed 2020-11-05 | 742.90K shares derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | 102.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 232.09K shares 10-Q · filed 2020-08-07 | 357.63K shares derived: sum of 3 quarters · filed 2020-08-07 | 580.83K shares derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | 130.07K shares 10-Q · filed 2020-05-07 | 255.61K shares derived: sum of 2 quarters · filed 2020-05-07 | 478.81K shares derived: sum of 3 quarters · filed 2020-05-07 | 792.91K shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 125.54K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 348.74K shares derived: sum of 2 quarters · filed 2020-02-27 | 662.84K shares derived: sum of 3 quarters · filed 2020-02-27 | 796.12K shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 223.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | 537.30K shares derived: sum of 2 quarters · filed 2019-11-06 | 670.58K shares 10-Q · filed 2019-11-06 | 808.17K shares derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | 314.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | 447.37K shares 10-Q · filed 2019-08-06 | 584.97K shares derived: sum of 3 quarters · filed 2019-08-06 | 634.74K shares derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | 133.27K shares 10-Q · filed 2019-05-08 | 270.87K shares derived: sum of 2 quarters · filed 2019-05-08 | 320.64K shares derived: sum of 3 quarters · filed 2019-05-08 | 443.44K shares derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | 137.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | 187.37K shares derived: sum of 2 quarters · filed 2019-03-12 | 310.16K shares derived: sum of 3 quarters · filed 2019-03-12 | 376.13K shares 10-K · filed 2019-03-12 |
| 2018-09-30 | 49.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 172.57K shares derived: sum of 2 quarters · filed 2018-11-08 | 238.54K shares 10-Q · filed 2018-11-08 | |
| 2018-06-30 | 122.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 188.77K shares 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 65.97K shares 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | 172.71K shares 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |